Written for the brain

Semax and selank are real registered medicines — just not where most readers live. Both were developed in Russia, both are prescribed there, and both are near-unknown to Western medicine. Semax is used for cognitive and neuroprotective indications; selank as an anti-anxiety agent. They arrive in the English-language peptide world as “nootropics,” which flattens something more interesting: these are drugs with a national clinical history, sitting in an evidentiary tradition that never fully connected to the one that produces FDA labels.

That gap is the subject here. The biology is plausible and in places genuinely elegant; the domestic use is decades deep; and the independent, Western-standard evidence is thin to absent. Holding all three at once — real mechanism, real use, missing audit — is the honest way to read a peptide from a different regulatory world. Bullish on the science, sceptical on the page.

Both peptides share a design philosophy this site keeps running into: take an endogenous human peptide, cut out the fragment that does the one thing you want, and armor it against the enzymes that would destroy it. Semax is a fragment of ACTH(4-10) — the stress hormone’s sequence — with its cortisol-releasing activity stripped away and a Pro-Gly-Pro tail bolted on to resist peptidase cleavage. It keeps the neuroactive clause of its parent and sheds the endocrine one.

That is exactly the move behind KPV, the anti-inflammatory tail cut from the melanocortin hormone α-MSH. Selank runs the same play on a different parent: it is a modified fragment of tuftsin, an immune-active peptide, re-pointed toward anxiety. In both cases the engineering is the believable part — a short, peptidase-resistant fragment that reaches the brain is a reasonable thing to build. What the fragment then does in a person is the part that needs evidence, not just a lineage.

Semax has the more worked-out mechanism. Rather than acting as a melanocortin hormone, it appears to raise brain-derived neurotrophic factor (BDNF) — the growth factor behind synaptic plasticity and neuronal survival — and its receptor TrkB. In rat hippocampus, a single dose of semax increased BDNF and trkB expression (Dolotov et al., Brain Res, 2006). A peptide that nudges the BDNF/TrkB system is a coherent story for a nootropic or a neuroprotectant, and it is consistent with the stroke and cognition indications semax carries in Russia.

The honest caveat is the altitude of that evidence. “Increases BDNF in rat hippocampus” is a mechanism in an animal, not a demonstrated clinical benefit in people. The leap from a neurotrophin bump in a rodent to a measurable cognitive or neuroprotective effect in a human is the same leap the whole nootropic field keeps gesturing past — and for semax, the controlled human trials that would close it are mostly unavailable outside their country of origin.

Selank’s strongest evidence is a single, genuinely interesting result. In a Russian randomized trial in generalized anxiety disorder and neurasthenia, selank’s anxiolytic effect was reported as comparable to the benzodiazepine medazepam — but without the sedation, and without the dependence that is the benzodiazepines’ defining liability (Zozulya et al., 2008). An anxiolytic that matches a benzodiazepine without the downsides would be a real advance if it held up.

“If it held up” is carrying the sentence. This is one modest trial, conducted in the drug’s home system, not an independently run, replicated program. In anxiety research especially — where placebo response is large and expectancy effects are strong — a single positive study from the originating tradition is a promising signal, not a settled conclusion. The result is good enough to make selank worth taking seriously and thin enough that taking it seriously means asking for the replication that does not yet exist.

The neuropeptide shelf holds a standing warning about how long a brain peptide can stay unresolved. Delta sleep-inducing peptide was pulled from the blood of sleeping rabbits in the 1970s and named for the deep-sleep waves it appeared to produce. Half a century on it is, in the words of its own review literature, an “unresolved riddle”: unambiguously endogenous, yet with no established receptor, no defined pathway, and a namesake sleep effect that has proven stubbornly hard to reproduce.

DSIP is the reminder that being real, named, and studied for fifty years does not add up to having a confirmed job. It is the failure mode every under-audited neuropeptide risks — a plausible story and a memorable name that outran the evidence and never got caught up with. Semax and selank are better supported than DSIP; the point is that “better than the peptide nobody could pin down” is not the same as established, and the direction they travel from here depends entirely on evidence that would have to come from outside the room that produced them.

• Registered drugs from a different system. Semax (cognition/neuroprotection) and selank (anxiety) are prescribed in Russia and nearly unknown to Western medicine — real clinical use, little external evidence.
• Engineered from endogenous fragments. Semax is ACTH(4-10) with the hormone activity removed and a peptidase-resistant tail added; selank is a modified tuftsin fragment — the same 'keep one clause' move as KPV.
• Semax's BDNF mechanism is animal-grade. A single dose raised BDNF and trkB in rat hippocampus — a coherent nootropic mechanism, but a rodent result, not a demonstrated human benefit.
• Selank has one promising trial. A Russian RCT found it comparable to a benzodiazepine without sedation — strong if replicated, but single and home-grown.
• DSIP is the warning label. An endogenous peptide named for a sleep effect that never reliably replicated. Real and memorable is not the same as established — the risk every under-audited neuropeptide carries.